28/09/2021
Renew® External Counterpulsation (ECP) Therapy System received a new clearance from the FDA for the treatment of healthy individuals. In addition to the well-known indication for the treatment of chronic stable angina, the Renew® ECP Therapy System is also "intended for use in healthy patients to provide improvement in vasodilation, increased VO2 and increased blood flow." The Renew® NCP-5 is the only ECP system with a cleared indication for the use in healthy patients.
Renew® ECP Therapy increases blood flow, vasodilation, and VO2 by enhancing blood flow throughout the body. During treatment, the patient's legs are compressed in coordination with the heart cycle. When the heart is at rest, this compression forces blood back to the heart and throughout the entire vascular system. This "counterpulsation" acts as an auxiliary pump benefitting the entire cardiovascular system and has been clinically proven to improve an individual's tolerance for activity1.
"There's a need from the patient base and we, as medical professionals, need to seek out technology to help solve the concerns and problems of our patients. Renew ECP Therapy is one of those technology pieces that patients are seeking," said Dr Ali, one of the doctor who look after their client at Lavmorenzo Wellness Centre in Petaling Jaya.